Anika Therapeutics | ANIK - Selling And Administration Expenses


Anika Therapeutics reported $10.01M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.13B 125M Dec/2025
Agenus USD 10.56M 13.04M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Integra LifeSciences USD 156.45M 12.6M Dec/2025
Intrexon USD 10.31M 41K Jun/2024
J&J USD 6.75B 831M Dec/2025
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
MacroGenics USD 7.94M 1.96M Dec/2025
Merit Medical Systems USD 114.83M 7.45M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Smith & Nephew USD 1.42B 65M Dec/2025
Stryker USD 2.14B 150M Dec/2025
Surmodics USD 11.4M 3.18M Jun/2025
Veracyte USD 43.31M 8.43M Dec/2025
Xencor USD 17.04M 70.74M Dec/2025
Zimmer Biomet Holdings USD 855.7M 44.3M Dec/2025